The European Commission has released MDCG 2020-16 rev.4, an updated guidance document on the classification of in vitro diagnostic medical devices under Regulation (EU) 2017/746. This revision introduces key changes to improve regulatory clarity and refine classification rules.
One notable update is the reclassification of SARS-CoV-2 tests: self-tests are now categorized as Class C, while tests for professional use fall under Class B. Additionally, examples for various classification rules, including Rule 1, Rule 4, and Rule 6, have been revised.
These adjustments aim to help manufacturers align their products with the latest regulatory requirements. Companies placing in vitro diagnostics on the EU market should carefully review the new guidelines to ensure compliance with the updated classification rules, especially when considering the extended transition period.
More details on the new version of the MDCG guidance can be found in our Library section.
Source: European Commission